Oh Young Bang/LinkedIn
Oct 6, 2025, 03:41
Oh Young Bang: We Are Carefully Preparing to Begin the First Cinical Trial of Exosome Therapy for Stroke in Korea
Oh Young Bang, Professor of Neurology at Samsung Medical Center, CEO at S and E bio, shared on LinkedIn:
”We are carefully preparing to begin the first clinical trial of exosome therapy for stroke in Korea, prioritizing safety over speed.”
Read more on the announcement here.
S and E Bio, a biotechnology company focused on exosomal microRNA-based therapies, has obtained approval from Korea’s Ministry of Food and Drug Safety (MFDS) to begin a Phase 1b clinical trial of its investigational stroke treatment, SNE-101.
This marks the first exosome-based therapy in Korea to advance to clinical trials, representing a significant milestone in the nation’s biopharmaceutical industry.
Stay updated with Hemostasis Today.
-
Nov 20, 2025, 19:04Giles Platford Joins the 2026 Healthcare Businesswomen’s Association Global Board of Directors
-
Nov 20, 2025, 18:40Mauricio Mandel on Cleveland Clinic’s Comprehensive Stroke Center Offer of VNS for Chronic Stroke
-
Nov 20, 2025, 18:20Joseph Italiano: Join Us to Pursue Cutting-Edge Research at the Interface of Megakaryocyte Biology
-
Nov 20, 2025, 18:06Akshat Jain Explores a New Blood Journals Study on the Bleeding Burden in Type 1 VWD
-
Nov 20, 2025, 17:40Marilena Vrana Announces the IPPC 2026 – Save the Date!
-
Nov 20, 2025, 17:29Thomas Pincez and Colleagues on Alterations in ITP
-
Nov 20, 2025, 17:11Nita Radhakrishnan Elected as a Fellow of the National Academy of Medical Sciences, Ministry of Health and Family Welfare
-
Nov 20, 2025, 16:47Khaled Musallam Takes on The Role as Chief of Cell/Gene Therapies and Hematology at Burjeel Cancer Institute
-
Nov 20, 2025, 16:26Sarah Matuja Presents Lessons from Tanzania’s Journey at UK Stroke Forum 2025